Hakutulokset - Barbara J. Gitlitz

Tarkenna hakua
  1. 1
    Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma

    Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma Tekijä Suresh S. Ramalingam, Chandra P. Belani, Christopher Ruel, Paul Frankel, Barbara J. Gitlitz, Marianna Koczywas, Igor Espinoza‐Delgado, David R. Gandara

    Julkaistu 2009
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  2. 2
    A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma

    A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma Tekijä Barbara J. Gitlitz, Carole Baker, Yvonne Chapman, Heather Allen, Linda D. Bosserman, Ravi Patel, J. Sanchez, Richard Shapiro, Robert A. Figlin

    Julkaistu 2003
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  3. 3
    Renal cell carcinoma with retroperitoneal lymph nodes

    Renal cell carcinoma with retroperitoneal lymph nodes Tekijä Allan J. Pantuck, Amnon Zisman, Frederich Dorey, Debby H. Chao, Ken‐ryu Han, Jonathan W. Said, Barbara J. Gitlitz, Arie S. Belldegrun, Robert A. Figlin

    Julkaistu 2003
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  4. 4
    Sorafenib in Platinum-Treated Patients with Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group (SWOG 0435) Phase II Trial

    Sorafenib in Platinum-Treated Patients with Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group (SWOG 0435) Phase II Trial Tekijä Barbara J. Gitlitz, James Moon, Bonnie S. Glisson, Hans Reimers, Martin J. Bury, Justin D. Floyd, Thomas K. Schulz, P. Kothai Sundaram, Christopher Ho, David R. Gandara

    Julkaistu 2010
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  5. 5
    Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib

    Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib Tekijä Linda Mileshkin, Rodney J. Hicks, Brett Hughes, Paul Mitchell, Veena Charu, Barbara J. Gitlitz, David Macfarlane, Benjamin Solomon, Lukas C. Amler, Wei Yu, Andrea Pirzkall, Bernard M. Fine

    Julkaistu 2011
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  6. 6
    Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Who Previously Progressed on Erlotinib

    Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Who Previously Progressed on Erlotinib Tekijä Primo N. Lara, Jeff Longmate, Philip C. Mack, Karen Kelly, Mark A. Socinski, Ravi Salgia, Barbara J. Gitlitz, Tianhong Li, M. Koczywas, Karen L. Reckamp, David R. Gandara

    Julkaistu 2015
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  7. 7
    Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer

    Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer Tekijä Suresh S. Ramalingam, Michael L. Maitland, Paul Frankel, Athanassios Argiris, Marianna Koczywas, Barbara J. Gitlitz, Sachdev Thomas, Igor Espinoza‐Delgado, Everett E. Vokes, David R. Gandara, Chandra P. Belani

    Julkaistu 2009
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  8. 8
    Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium

    Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium Tekijä Nicholas Campbell, Rangesh Kunnavakkam, Natasha B. Leighl, Mark Vincent, David R. Gandara, Marianna Koczywas, Barbara J. Gitlitz, Edem Agamah, Sachdev Thomas, Walter M. Stadler, Everett E. Vokes, Hedy L. Kindler

    Julkaistu 2012
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  9. 9
    Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?

    Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure t... Tekijä Sai‐Hong Ignatius Ou, Thomas K. Lee, Lauren Young, Maria Y. Fernandez-Rocha, Dean Pavlick, Alexa B. Schrock, Viola W. Zhu, Jeffrey C. Milliken, Siraj M. Ali, Barbara J. Gitlitz

    Julkaistu 2017
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  10. 10
    IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) + chemotherapy

    IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) + chemotherapy Tekijä Solange Peters, A.W. Kim, Benjamin Solomon, David R. Gandara, Rafał Dziadziuszko, Alessandro Brunelli, Marina Chiara Garassino, Martin Reck, L. Wang, Ikpesu TO, Si Sun, Barbara J. Gitlitz, A. Sandler, Naiyer A. Rizvi

    Julkaistu 2019
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  11. 11
    Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer

    Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small... Tekijä Janessa Laskin, Garth Nicholas, Christopher Lee, Barbara J. Gitlitz, Mark Vincent, Yvon Cormier, Joe Stephenson, Yee Ung, Rachel E. Sanborn, Bryn Pressnail, F. Warren Nugent, John Nemunaitis, Martin Gleave, Nevin Murray, Desirée Hao

    Julkaistu 2011
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  12. 12
    Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer

    Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer Tekijä Lecia V. Sequist, Benjamin Besse, Thomas J. Lynch, Vincent A. Miller, Kwok‐Kin Wong, Barbara J. Gitlitz, Keith D. Eaton, Charles Zacharchuk, Amy Freyman, Christine Powell, Revathi Ananthakrishnan, Susan Quinn, Jean‐Charles Soria

    Julkaistu 2010
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  13. 13
    Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303)

    Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epider... Tekijä Karen L. Reckamp, Paul Frankel, Nora Ruel, Philip C. Mack, Barbara J. Gitlitz, Tianhong Li, Marianna Koczywas, Shirish M. Gadgeel, Mihaela Cristea, Chandra P. Belani, Edward M. Newman, David R. Gandara, Primo N. Lara

    Julkaistu 2019
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  14. 14
    Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors

    Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors Tekijä Adil Daud, Smitha Krishnamurthi, Mansoor N. Saleh, Barbara J. Gitlitz, Mitesh J. Borad, Philip J. Gold, Elena G. Chiorean, Gregory M. Springett, Richat Abbas, Shefali Agarwal, Nathalie Bardy‐Bouxin, Poe‐Hirr Hsyu, Eric Leip, Kathleen Turnbull, Charles Zacharchuk, Wells A. Messersmith

    Julkaistu 2011
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  15. 15
    HER2 V659 and G660 transmembrane mutations that stabilize homo- and hetero-dimerization are rare oncogenic drivers in lung adenocarcinoma that are clinically responsive to afatinib

    HER2 V659 and G660 transmembrane mutations that stabilize homo- and hetero-dimerization are rare oncogenic drivers in lung adenocarcinoma that are clinically responsive to afatinib Tekijä S.-H.I. Ou, Alexa B. Schrock, Eduard V. Bocharov, Samuel J. Klempner, Charbel Haddad, Gary Steinecker, Melissa L. Johnson, Barbara J. Gitlitz, Jon Chung, Paulo Vidal Campregher, J.S. Ross, P. Stephens, V.A. Miller, James Suh, Siraj M. Ali, Vamsidhar Velcheti

    Julkaistu 2016
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  16. 16
    HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib

    HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib Tekijä Sai‐Hong Ignatius Ou, Alexa B. Schrock, Eduard V. Bocharov, Samuel J. Klempner, Carolina Kawamura Haddad, Gary Steinecker, Melissa L. Johnson, Barbara J. Gitlitz, Jon Chung, Paulo Vidal Campregher, Jeffrey S. Ross, Philip J. Stephens, Vincent A. Miller, James Suh, Siraj M. Ali, Vamsidhar Velcheti

    Julkaistu 2016
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  17. 17
    2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC

    2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSC... Tekijä C. Zhou, Meghna Das Thakur, Manoj Srivastava, Wen Zou, Hongjie Xu, M. Ballinger, Enriqueta Felip, Heather A. Wakelee, Nasser K. Altorki, Martin Reck, Rüediger Liersch, Anna Kryzhanivska, M. Harada, Hiroshi Tanaka, John Hamm, Steve McCune, Virginia McNally, Elizabeth Bennett, Barbara J. Gitlitz, Silvia Novello

    Julkaistu 2021
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  18. 18
    Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

    Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study Tekijä Leora Horn, Jeffrey R. Infante, Karen L. Reckamp, George R. Blumenschein, Ticiana Leal, Saiama N. Waqar, Barbara J. Gitlitz, Rachel E. Sanborn, Jennifer G. Whisenant, Liping Du, Joel W. Neal, Jon P. Gockerman, Gary Dukart, Kimberly Harrow, Chris Liang, James J. Gibbons, Allison Holzhausen, Christine M. Lovly, Heather A. Wakelee

    Julkaistu 2018
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  19. 19
    Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer

    Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer Tekijä C.A. Carter, Arun Rajan, Corrine Keen, Éva Szabó, Sean Khozin, Adam D. Thomas, Christina Brzezniak, Udayan Guha, L. Austin Doyle, Seth M. Steinberg, Liqiang Xi, Mark Raffeld, Yusuke Tomita, Min-Jung Lee, S. Lee, Jane B. Trepel, Karen L. Reckamp, S. Koehler, Barbara J. Gitlitz, Ravi Salgia, David Gandara, Everett E. Vokes, Giuseppe Giaccone

    Julkaistu 2016
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  20. 20
    <i>EGFR</i> Fusions as Novel Therapeutic Targets in Lung Cancer

    <i>EGFR</i> Fusions as Novel Therapeutic Targets in Lung Cancer Tekijä Kartik Konduri, Jean‐Nicolas Gallant, Young Kwang Chae, Francis J. Giles, Barbara J. Gitlitz, Kyle Gowen, Eiki Ichihara, Taofeek K. Owonikoko, Vijay Peddareddigari, Suresh S. Ramalingam, Satyanarayan K. Reddy, Beth Eaby‐Sandy, Tiziana Vavalà, Andrew R. Whiteley, Heidi Chen, Yingjun Yan, Jonathan H. Sheehan, Jens Meiler, Deborah Morosini, Jeffrey S. Ross, Philip J. Stephens, Vincent A. Miller, Siraj M. Ali, Christine M. Lovly

    Julkaistu 2016
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:

Työkalut: